Novadip Biosciences is a Belgian late-stage clinical biotechnology company specializing in regenerative medicine, founded in 2013 in Mont Saint-Guibert as a spin-off of research by founder Prof. Denis Dufrane at UCLouvain and St. Luc University Hospital. Its proprietary 3M³ tissue regeneration platform develops regenerative tissue products that heal large bone defects, bone non-union and spine fusion in a single treatment. Lead candidate NVD003, an autologous cell-based therapy, is in pivotal Phase 3 trials for congenital pseudarthrosis of the tibia in the US and EU, while NVDX3, an allogenic bone grafting material, has completed Phase 1b/2a studies with FDA clearance to begin a Phase 2b/3 trial. The company has 53 employees and has raised EUR 137 million in equity and non-dilutive funding since inception.
1
Round
1
Industry
5
Tags
Sep 21, 2026
Latest raise
Funding activity · 1 round
Sep 21, 2026
EUR 10.4M
Debt
Led by New Science Ventures
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
